Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
Authors' conclusion
The extensive assessment of once-weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in chronic weight management.
Study context
- Population
- Adults with BMI ≥ 27 kg/m² with or without T2D4 trials
- Comparison
- Once-weekly subcutaneous tirzepatide vs placebo, adjunct to lifestyle intervention
- Primary endpoint
- Percentage change in body weight
- Follow-up
- Randomization to end of treatment
Methodological detailsfour randomised controlled trials, global, double-blind, placebo-controlled
- Four randomised controlled trials
- Global
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Baseline characteristics across trials
Mean age
44.9 to 54.2 years
Female
50.7% to 69.7%
Mean BMI
36.1 to 38.9
Original publication
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). Published 7 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →